Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CDK2 | P24941 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060507 | 0.85 | MKNK1 (0.72) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| SCHEMBL29141649 | 0.81 | BRD4 (0.62) | LMNATSHRHTTHSD17B10SMN1; SMN2 | |
| SCHEMBL28818322 | 0.79 | LMNA (0.74) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| SCHEMBL3038563 | 0.78 | NPC1 (0.76) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| SCHEMBL405823 | 0.76 | HTT (0.58) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| SCHEMBL29501839 | 0.75 | LMNA (0.57) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| 6-Benzylaminopurine SCHEMBL37358 | 0.75 | LMNA (1.00) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| 6-Benzylaminopurine SCHEMBL29349525 | 0.75 | LMNA (1.00) | LMNAMAPK1TSHRCYP1A2CYP2D6 | |
| SCHEMBL29141653 | 0.75 | HTT (0.50) | LMNAMAPK1TSHRCYP1A2CDK2 | |
| SCHEMBL29141645 | 0.75 | SMN1; SMN2 (0.63) | LMNAMAPK1TSHRHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2026-04-30 | — | — | US | disclosed |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | CAN-FITE BIOPHARMA LTD. (IL) | 2025-02-04 | — | — | US | disclosed |
| EP-3530273-B1 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN THE TREATMENT OF A SEXUAL DYSFUNCTION | CAN FITE BIOPHARMA LTD (IL) | 2024-08-14 | — | — | EP | disclosed |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | disclosed |
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | CAN-FITE BIOPHARMA LTD. (IL) | 2022-04-05 | — | — | US | disclosed |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291681-B2 | Method for treating fibrotic liver tissue using Cl-IB-MECA | GPR119, FABP1, INSR | LMNA 1080/4885MAPK1 4869/4885TSHR 114/4885 |
| US-20220079968-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | ADORA2A, ADORA3, FABP4 | LMNA 1275/4885MAPK1 4036/4885TSHR 211/4885 |
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | LMNA 3089/4885MAPK1 4592/4885TSHR 70/4885 |
| US-20260115218-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA2B, ADORA3, ADORA2A | LMNA 723/4885MAPK1 4693/4885TSHR 131/4885 |
| US-12213990-B2 | A3 adenosine receptor ligand for use for achieving a fat loss effect | ADORA3, ADORA2A, FABP4 | LMNA 1415/4885MAPK1 3915/4885TSHR 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.